Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Glycogen storage disease (GSD) type Ib is a congenital disorder of glycogen metabolism that is associated with neutropenia, neutrophil dysfunction, and an inflammatory bowel disease that mimics a Crohn phenotype. Gastrointestinal inflammation in GSD Ib has been successfully treated with 5-aminosalicylic acid and granulocyte colony-stimulating factor (G-CSF). However, therapeutic options for patients not responding to traditional therapies have been limited owing to untoward effects of glucocorticoids and immunomodulators in this metabolic disorder. Adalimumab is a monoclonal antibody targeting tumour necrosis factor-α that has shown promise for the treatment of patients with Crohn disease. Due to the limited options for treating GSD-associated inflammatory bowel disease, use of adalimumab was attempted in a case unresponsive to aminosalicylate, G-CSF, and antibiotic therapy. Significant clinical and histological improvement was observed in our patient, and the medication was well tolerated.
- Chen YT, Bazzarre CH, Lee MM, et al (1993) Type I glycogen storage disease: nine years of management with cornstarch. Eur J Pediatr 152(Supplement 1): S56–59. CrossRef
- Chen Y-T, Burchell A (2001) Glycogen storage diseases. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1521–1551.
- De Jong DJ, Tielen J, Habraken CM, et al (2005) 5-Aminosalicylates and effects on renal function in patients with Crohn’s disease. Inflamm Bowel Dis 11(11): 972–976. CrossRef
- Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L (2002) Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr 161(Supplement 1): S88–92.
- Gitzelmann R, Bosshard NU (1993) Defective neutrophil and monocyte functions in glycogen storage disease type Ib: a literature review. Eur J Pediatr 152(Supplement 1): S33–38. CrossRef
- Glas J, Torok HP, Daczo J, et al (2005) The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur J Med Res 10(12): 535–538.
- Hanauer SB, Feagan BG, Lichtenstein GR, et al (2002) ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317): 1541–1549. CrossRef
- Hanauer SB, Sandborn WJ, Rutgeerts P, et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130(2): 323–333. CrossRef
- Korzenik JR, Dieckgraefe BK (2005) An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn’s disease. Aliment Pharmacol Ther 21(4): 391–400. CrossRef
- Lawson MM, Thomas AG, Akobeng AK (2006) Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 3: CD005112.
- Lei KJ, Shelly LL, Lin B, et al (1995) Mutations in the glucose-6-phosphatase gene are associated with glycogen storage disease types Ia and IaSP but not 1b and 1c. J Clin Invest 95(1): 234–240.
- Lei KJ, Shelly LL, Pan CJ, et al (1993) Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type Ia. Science 262(5133): 580–583. CrossRef
- Roe TF, Thomas DW, Gilsanz V, et al (1986) Inflammatory bowel disease in glycogen storage disease type Ib. J Pediatr 109(1): 55–59. CrossRef
- Rutgeerts P, Sandborn WJ, Feagan BG, et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23): 2462–2476. [Erratum in N Engl J Med 2006; 354(20): 2200.] CrossRef
- Visser G, Rake JP, Fernandes J, et al (2000) Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr 137(2): 187–191. CrossRef
- Visser G, Rake JP, Labrune P, et al (2002) Consensus guidelines for management of glycogen storage disease type 1b—European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 161(Supplement 1): S120–123.
- Wolfsdorf JI, Crigler JF Jr (1997) Cornstarch regimens for nocturnal treatment of young adults with type I glycogen storage disease. Am J Clin Nutr 65(5): 1507–1511.
- Wolfsdorf JI, Crigler JF Jr (1999) Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease. J Pediatr Gastroenterol Nutr 29(2): 136–143. CrossRef
- Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib
Journal of Inherited Metabolic Disease
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Division of Pediatric Gastroenterology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA
- 2. Division of Gastroenterology and Nutrition and Center for Inflammatory Bowel Disease, Children’s Hospital Boston, Boston, Massachusetts, USA
- 3. Division of Gastroenterology, Hepatology & Nutrition, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
- 4. Division of Pediatric Endocrinology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA
- 5. Glycogen Storage Disease Program, University of Florida College of Medicine, Gainesville, FL, 32610, USA